Roche, headquartered in Basel, Switzerland, is one of the worldÔÇÖs leading research-intensive healthcare groups. Its core businesses are pharmaceuticals and diagnostics. As a supplier of innovative products and services for the prevention, diagnosis and treatment of disease, the group contributes on a broad range of fronts to improving peopleÔÇÖs health and quality of life. Roche is a global leader in diagnostics, the leading supplier of medicines for cancer and transplantation, and a market leader in virology. Roche employs roughly 70,000 people in 150 countries and has research and development (R&D) agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai.
RocheÔÇÖs Diagnostics Division, a world leader in diagnostics with a uniquely broad product portfolio, supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals, and laboratories worldwide. Applied Science develops and markets components and reagents for the pharmaceuticals and diagnostics industries, new technologies for medical research, and innovative products for use in biotechnology. Molecular Diagnostics made polymerase chain reaction (PCR) the leading DNA probe technology in the world. This area is focused on developing and commercializing six unique PCRs, businesseswomenÔÇÖs health, virology, blood screening, microbiology, oncology, and genomics. It is truly dedicated to innovations using this Nobel Prize-winning technology. Centralized Diagnostics is a leading supplier of integrated system solutions for laboratories. This clinical diagnostics area develops and supplies new technologies and integrated solutions that help clinical laboratories to operate efficiently and be cost-effective. Point of Care Diagnostics supplies products and systems for near patient diagnostic testing in hospitals and outpatient settings. Diabetes Care as the leading supplier of comprehensive diabetes management solutions, Diabetes Care is dedicated to developing technologies and services under the ACCU-CHEK┬« brand, which help make living with diabetes easier.
Worldwide, more than 19,000 people are engaged in research, development, marketing and sales of products, services, and integrated solutions of Roche Diagnostics. With affiliates in more than 50 countries, Roche Diagnostics continuously strives to serve its customers in a way to make them more efficient and generate value to customers, employees, shareholders, and the community.
- O'Donoghue M, Chen A, Baggish A et al., Massachusetts General Hospital, Boston, Massachusetts. NT-proBNP is superior to BNP for the evaluation of patients with dyspnea and non-systolic congestive heart failure: A proBNP investigation of dyspnea in the emergency department (PRIDE) substudy; JACC (2005); Suppl A:45:3:Abstract No. 170.
- Krauser DG, Lloyd-Jones DM, Chae CU et al., Boston, Massachusetts and Chicago Ill. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A proBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy; Am Heart J (2005); 149:pp. 744-750.
Crossref | PubMed
- Siebert U, Januzzi JL, Beinfeld MT et al., Institute For Technology Assessment, Massachusetts General Hosp, Harvard Med School, Boston, Massachusetts. Circulation (2004); 110:pp. 369 (Suppl III).